Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

Targeted cancer therapies often induce “outlier” responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA s...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Imielinski, Marcin, Greulich, Heidi, Kaplan, Bethany, Araujo, Luiz, Amann, Joseph, Horn, Leora, Schiller, Joan, Villalona-Calero, Miguel A., Meyerson, Matthew, Carbone, David P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2014
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3973082/
https://ncbi.nlm.nih.gov/pubmed/24569458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI72763
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak